Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Eileen Holmes"'
Autor:
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the imm
Externí odkaz:
https://doaj.org/article/c541e25cb1954a448e8d1d99ad81395d
Publikováno v:
International Journal of Technology Assessment in Health Care. 39
Objectives The Scottish Medicines Consortium (SMC) conducts early health technology assessment (HTA) of new medicines on behalf of NHSScotland. Assessment of end-of-life (EoL), orphan, and ultra-orphan medicines includes a process to gather evidence
Autor:
Garrick Kassab, José Baselga, Alvaro Moreno-Aspitia, Otto Metzger Filho, Richard D. Gelber, David W. Hillman, Kamal S Saini, Christine Campbell, Ann E. McCullough, Larissa A. Korde, Antonio C. Wolff, Masakazu Toi, Kathleen I. Pritchard, Miguel Izquierdo, Zeba Aziz, Daniela Dornelles Rosa, Frances M. Boyle, Ian E. Smith, Celine Schurmans, Georgia Demetriou, István Láng, Michael Untch, Binghe Xu, Zhimin Shao, Eileen Holmes, Evandro de Azambuja, Carlos Barrios, Eleanor McFadden, Martin Andersson, Martine Piccart-Gebhart, Debora Fumagalli, Sung Hoon Sim, Robin McConnell, Christian Jackisch, Ajay O. Mehta, Sarra El-Abed, Vicki Paterson, Emma Paterson, Florentine Hilbers, Michael S. Ewer, Vasiliki Balta, Sebastien Guillaume
Publikováno v:
Eur J Cancer
Aim To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients and methods 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L
Publikováno v:
International Journal of Technology Assessment in Health Care. 37:8-8
IntroductionThe Scottish Medicines Consortium (SMC) conducts early health technology assessment (HTA) of new medicines on behalf of NHSScotland. Evidence from patients and carers on end-of-life and orphan medicines is gathered during Patient and Clin
Autor:
Daniel E. Carvajal-Hausdorf, Eileen Holmes, J. Baselga, Vanessa Rodrik-Outmezguine, Debora Fumagalli, David L. Rimm, M.J. Piccart, L delaPena, J Huober, L Pusztai, E deAzambuja, Nadia Harbeck
Publikováno v:
Cancer Research. 78:P2-09
Background: Preclinical models suggest that in some HER2 overexpressed breast cancer cases, the extracellular domain of HER2, containing the binding region for trastuzumab (T) is not present due to proteolytic cleavage. Previous measurement of HER2 E
Autor:
Eileen Holmes, Debora Fumagalli, A. Moreno-Aspitia, R. D. Gelber, E. de Azambuja, Amylou C. Dueck, Martine Piccart-Gebhart, Ian Bradbury, Larissa A. Korde, José Baselga, L.S. Williams
Publikováno v:
Ann Oncol
Background Design, conduct, and analysis of randomized clinical trials (RCTs) with time to event end points rely on a variety of assumptions regarding event rates (hazard rates), proportionality of treatment effects (proportional hazards), and differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47290e8f52ee9fc52068148926cea858
https://europepmc.org/articles/PMC6931237/
https://europepmc.org/articles/PMC6931237/
Publikováno v:
Research synthesis methodsREFERENCES. 10(4)
Indirect treatment comparisons are useful to estimate relative treatment effects when head-to-head studies are not conducted. Statisticians at the National Centre for Pharmacoeconomics Ireland (NCPE) and Scottish Medicines Consortium (SMC) assess the
Autor:
Christian Jackisch, Christophe Lecocq, Serena Di Cosimo, Frances M. Boyle, José Baselga, Michael Untch, Ian E. Smith, Eileen Holmes, Hans Wildiers, Debora Fumagalli, Martine Piccart-Gebhart, Jens Huober, Hryhoriy Adamchuk, Lorena de la Peña, Richard D. Gelber, Tamas Hickish, John Hackman, Binghe Xu, Evandro de Azambuja, Eva Ciruelos, Juan Carlos Toral Pena, Severine Sarp, Lokanatha Dasappa, István Láng, Christelle Jouannaud
Publikováno v:
European journal of cancer (Oxford, England : 1990). 118
BACKGROUND: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti-human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-fr
Autor:
Valentina Nekljudova, José Baselga, Sherene Loi, Ian J. Majewski, René Bernards, Martine Piccart, Emilio Bria, Christian Schem, Pierfranco Conte, Michael Untch, Christos Sotiriou, Eileen Holmes, Carsten Denkert, Sibylle Loibl, G. von Minckwitz, Valentina Guarneri
Publikováno v:
Annals of oncology, 29 (10
Annals of oncology
Annals of oncology
The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the power for subgroup analyses was lacking.We combined individual patient data from five clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7e1e39f9aa36ceceaafea19a4eadbe
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283377
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283377
Autor:
Chiun-Sheng Huang, Christian Jackisch, Michael Untch, A Armour, David W. Hillman, Jo Anne Zujewski, Eleanor McFadden, Stella Dolci, Véronique Diéras, Jośe Baselga, Amylou C. Dueck, Sergei Tjulandin, Edith A. Perez, Antonio C. Wolff, Holger Eidtmann, Frances M. Boyle, Young-Hyuck Im, Kathleen I. Pritchard, Ian E. Smith, Thomas M. Suter, Andrew P. Holmes, Evandro de Azambuja, Giuseppe Viale, Serena Di Cosimo, Liu Tong-hua, Eileen Holmes, Binghe Xu, Aron Goldhirsch, Richard D. Gelber, Henry L. Gomez, Ann E. McCullough, Martine Piccart-Gebhart, István Láng, Nadia Harbeck, Phuong Dinh
Publikováno v:
Journal of Clinical Oncology. 34:1034-1042
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy rema